fibrinolytic [topp]
Increased [qnco]
Estrogen [horm, phsu, strd]
treatment [ftcn]
postmenopausal [tmco]
Women [popg]
Mild [qlco]
Dyslipidaemia [dsyn]
Objective [inpr]
Study [mnob]
effects [qlco]
Estrogen Replacement [topp]
treatment [ftcn]
fibrinolytic [topp]
postmenopausal [tmco]
Women [popg]
Design [acty]
DOUBLE BLIND [resa]
placebo-controlled [resa]
Trial [resa]
Oral [spco]
17 beta-Estradiol [horm, phsu, strd]
setting [ftcn]
Subject [grup]
Evaluated [ftcn]
Out-patient [podg]
setting [ftcn]
Patients [podg]
postmenopausal [tmco]
Women [popg]
Mild [qlco]
Dyslipidaemia [dsyn]
Aged [orga]
Main [qlco]
Outcome Measures [qnco]
fibrinolytic [topp]
activity [dora]
Fibrin [aapp, bacs, phsu]
Plate assay [lbpr]
Tissue Plasminogen Activator Antigen [imft]
Measured [qlco]
baseline [bodm]
Six [qnco]
Nine [qnco]
weeks [tmco]
treatment [ftcn]
Nine [qnco]
weeks [tmco]
mg% [qnco]
Estradiol [horm, phsu, strd]
treatment [ftcn]
fibrinolytic [topp]
Compared [acty]
placebo [topp]
Indicated [fndg]
fibrinolytic [topp]
activity [dora]
SEM [medd]
Lysis [patf]
Fibrin [aapp, bacs, phsu]
Plate [medd]
mg% [qnco]
placebo [topp]
P NOS [aapp, imft]
Decrease [qlco]
Tissue Plasminogen Activator Antigen [imft]
mg% [qnco]
placebo [topp]
P NOS [aapp, imft]
trend [tmco]
mg% [qnco]
Dose [qnco]
Conclusions [idcn]
hormone treatment [topp]
Replacement [topp]
17 beta-Estradiol [horm, phsu, strd]
Nine [qnco]
weeks [tmco]
Increased [qnco]
fibrinolytic [topp]
postmenopausal [tmco]
Women [popg]
Mild [qlco]
Dyslipidaemia [dsyn]
Suggest [idcn]
Estrogen [horm, phsu, strd]
mediated [socb]
Part [spco]
fibrinolytic [topp]
